Nivolumab and Pembrolizumab As Immune-Modulating Monoclonal Antibodies Targeting the Pd-1 Receptor to Treat Melanoma

Science Communicator Platform

Share By

Nivolumab and Pembrolizumab As Immune-Modulating Monoclonal Antibodies Targeting the Pd-1 Receptor to Treat Melanoma Publisher Pubmed

Faghfuri E¹ ; Faramarzi MA¹ ; Nikfar S² ; Abdollahi M^{3, 4}

Source: Expert Review of Anticancer Therapy Published:2015

Abstract

Malignant melanoma is an important issue in oncology due to its high incidence, high mortality, and resistance to systemic therapy; however, targeted immunotherapy has noticeably improved the survival rates of melanoma patients. Promising targeted immunotherapies for malignant melanoma include the blockade of immune checkpoints with antibodies targeting cytotoxic T lymphocyte-associated antigen 4 and the programmed cell death protein 1 pathway. The US FDA-approved antibody ipilimumab targets cytotoxic T lymphocyte-associated antigen 4; however, it was limited by toxicity and a low response. Nivolumab and pembrolizumab (formerly lambrolizumab), the two FDA-approved anti-programmed death-1 monoclonal antibodies, show highly durable response rates and long-term safety, validating the importance of the programmed cell death protein 1 pathway blockade for treatment of malignant melanoma. © 2015 Informa UK, Ltd.

Related Docs

View other Related Docs

1. Pd-1 and Cancer: Molecular Mechanisms and Polymorphisms, Immunogenetics (2018)

2. Immunotherapy of Cancers Comes of Age, Expert Review of Clinical Immunology (2017)

3. Targeting the Pd-1/Pd-L1 Pathway in Glioblastoma Multiforme: Preclinical Evidence and Clinical Interventions, International Immunopharmacology (2021)

Experts (# of related papers)

View all Related Experts

Nima Rezaei (9)

Laleh Sharifi (1)

Other Related Docs

4. Immune Checkpoint Inhibitor (Ici) Therapy in Central Nervous System Cancers: State-Of-The-Art and Future Outlook, International Immunopharmacology (2025)

5. Immune Therapy of Melanoma: Overview of Therapeutic Vaccines, Journal of Cellular Physiology (2019)

6. Tumor Immunology, Clinical Immunology (2022)

7. Immune Checkpoints and Graves’ Disease, Thyroid Eye Disease, and Orbital Myopathy: A Comprehensive Review, Journal of Ophthalmic and Vision Research (2024)

8. The Promising Role of Monoclonal Antibodies for Gastric Cancer Treatment, Immunotherapy (2019)

9. Immune Checkpoint Blockade in Melanoma: Advantages, Shortcomings and Emerging Roles of the Nanoparticles, International Immunopharmacology (2022)

10. Exhaustion of T Lymphocytes in the Tumor Microenvironment: Significance and Effective Mechanisms, Cellular Immunology (2017)

11. Tumor Immunotherapies by Immune Checkpoint Inhibitors (Icis); the Pros and Cons, Cell Communication and Signaling (2022)

12. Review of the Recent Clinical Trials for Pd-1/Pd-L1 Based Lung Cancer Immunotherapy, Expert Review of Anticancer Therapy (2021)

13. Pd-1/Pd-L1 Pathway: Basic Biology and Role in Cancer Immunotherapy, Journal of Cellular Physiology (2019)

14. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)

15. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)

16. Cancer Immunotherapy Confers a Global Benefit, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)

17. The Potential of T Cell Immunoglobulin and Mucin-Domain Containing-3 (Tim-3) in Designing Novel Immunotherapy for Bladder Cancer, Endocrine# Metabolic and Immune Disorders - Drug Targets (2021)

18. Chimeric Antigen Receptor T-Cell Therapy for Melanoma, Expert Review of Clinical Immunology (2021)

19. Prognostic Value of 2-[18F]Fdg Pet-Ct in Metastatic Melanoma Patients Receiving Immunotherapy, European Journal of Radiology (2022)

20. Recent Advances on Immune Targeted Therapy of Colorectal Cancer Using Bi-Specific Antibodies and Therapeutic Vaccines, Biological Procedures Online (2021)

Style	Citing Format
MLA	Faghfuri E, et al.. "Nivolumab and Pembrolizumab As Immune-Modulating Monoclonal Antibodies Targeting the Pd-1 Receptor to Treat Melanoma." Expert Review of Anticancer Therapy, vol. 15, no. 9, 2015, pp. 981-993.
APA	Faghfuri E, Faramarzi MA, Nikfar S, Abdollahi M (2015). Nivolumab and Pembrolizumab As Immune-Modulating Monoclonal Antibodies Targeting the Pd-1 Receptor to Treat Melanoma. Expert Review of Anticancer Therapy, 15(9), 981-993.
Chicago	Faghfuri E, Faramarzi MA, Nikfar S, Abdollahi M. "Nivolumab and Pembrolizumab As Immune-Modulating Monoclonal Antibodies Targeting the Pd-1 Receptor to Treat Melanoma." Expert Review of Anticancer Therapy 15, no. 9 (2015): 981-993.
Harvard	Faghfuri E et al. (2015) 'Nivolumab and Pembrolizumab As Immune-Modulating Monoclonal Antibodies Targeting the Pd-1 Receptor to Treat Melanoma', Expert Review of Anticancer Therapy, 15(9), pp. 981-993.
Vancouver	Faghfuri E, Faramarzi MA, Nikfar S, Abdollahi M. Nivolumab and Pembrolizumab As Immune-Modulating Monoclonal Antibodies Targeting the Pd-1 Receptor to Treat Melanoma. Expert Review of Anticancer Therapy. 2015;15(9):981-993.
BibTex	@article{ author = {Faghfuri E and Faramarzi MA and Nikfar S and Abdollahi M}, title = {Nivolumab and Pembrolizumab As Immune-Modulating Monoclonal Antibodies Targeting the Pd-1 Receptor to Treat Melanoma}, journal = {Expert Review of Anticancer Therapy}, volume = {15}, number = {9}, pages = {981-993}, year = {2015} }
RIS	TY - JOUR AU - Faghfuri E AU - Faramarzi MA AU - Nikfar S AU - Abdollahi M TI - Nivolumab and Pembrolizumab As Immune-Modulating Monoclonal Antibodies Targeting the Pd-1 Receptor to Treat Melanoma JO - Expert Review of Anticancer Therapy VL - 15 IS - 9 SP - 981 EP - 993 PY - 2015 ER -

Science Communicator Platform

Authors

Abstract